- Home
- ADTX vs CERO Comparison
ADTX vs CERO Comparison
Compare ADTX & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTX
- CERO
- Stock Information
- Founded
- ADTX 2017
- CERO 2017
- Country
- ADTX United States
- CERO United States
- Employees
- ADTX N/A
- CERO N/A
- Industry
- ADTX Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- ADTX Health Care
- CERO
- Exchange
- ADTX Nasdaq
- CERO Nasdaq
- Market Cap
- ADTX 3.1M
- CERO 3.5M
- IPO Year
- ADTX 2020
- CERO N/A
- Fundamental
- Price
- ADTX $1.20
- CERO $8.73
- Analyst Decision
- ADTX
- CERO Strong Buy
- Analyst Count
- ADTX 0
- CERO 2
- Target Price
- ADTX N/A
- CERO $45.00
- AVG Volume (30 Days)
- ADTX 2.0M
- CERO 335.7K
- Earning Date
- ADTX 08-18-2025
- CERO 08-13-2025
- Dividend Yield
- ADTX N/A
- CERO N/A
- EPS Growth
- ADTX N/A
- CERO N/A
- EPS
- ADTX N/A
- CERO N/A
- Revenue
- ADTX $55,323.00
- CERO N/A
- Revenue This Year
- ADTX $15,768.94
- CERO N/A
- Revenue Next Year
- ADTX N/A
- CERO N/A
- P/E Ratio
- ADTX N/A
- CERO N/A
- Revenue Growth
- ADTX N/A
- CERO N/A
- 52 Week Low
- ADTX $1.05
- CERO $6.71
- 52 Week High
- ADTX $21,400.00
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- ADTX 39.51
- CERO 46.35
- Support Level
- ADTX $1.13
- CERO $8.19
- Resistance Level
- ADTX $1.30
- CERO $9.02
- Average True Range (ATR)
- ADTX 0.11
- CERO 0.44
- MACD
- ADTX 0.03
- CERO 0.02
- Stochastic Oscillator
- ADTX 46.81
- CERO 30.03
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.